Key Takeaways
- A 2024 mystery-caller study published in the Journal of the American Academy of Orthopaedic Surgeons found that Medicaid patients were denied appointments or quoted longer wait times than privately insured callers at orthopaedic practices nationwide.
- A scoping review in the Journal of Medical Internet Research identified no consistent public reimbursement model for telemedicine across national or subnational jurisdictions, leaving providers and patients exposed to unpredictable out-of-pocket costs.
- A critical review in the Journal of Substance Use and Addiction Treatment documented that prior authorization requirements, pharmacy benefit restrictions, and low reimbursement rates are the primary payment barriers blocking access to medications for opioid use disorder.
- A secondary analysis of a randomized clinical trial published in JAMA Internal Medicine found that the Care Ecosystem collaborative model reduced Medicare costs for dementia patients, yet such models remain rare and unevenly funded.
- Qualitative research on Ghana’s Akoma Pa mHealth telemedicine program shows that even when telemedicine infrastructure exists, undefined pricing and absent reimbursement agreements cause implementers to stall or abandon services.
How often are Medicaid patients turned away by specialist offices?
Medicaid patients are turned away by specialist offices at striking rates — and a 2024 national study put hard numbers on a problem that patients have long reported anecdotally. Researchers posing as new patients called orthopedic surgeon offices across the country and found that Medicaid coverage and access to specialized surgeons is sharply unequal: Medicaid callers were denied appointments far more often than callers with private insurance, with some specialties and regions showing refusal rates above 50%.
The mechanism is straightforward. Medicaid reimbursement rates for specialist visits are set by state governments, and in most states those rates sit well below what private insurers pay for the same service. A specialist who accepts a Medicaid patient for a consultation may collect $80–$120 where a commercially insured patient generates $250 or more. Offices running on thin margins make a business decision, not a clinical one, when they close their schedules to Medicaid.
The orthopedic mystery-caller study uncovered specific patterns. Offices frequently told Medicaid callers they were “not accepting new patients” while offering appointments to callers with private insurance within days. Refusal rates varied by state, tracking closely with how low each state’s Medicaid fee schedule sits relative to Medicare rates. Rural offices showed higher refusal rates than urban ones, compounding geographic barriers that already limit specialist access in those areas.
This matters for telehealth specifically because many patients turn to virtual care after being turned away in person. Telehealth platforms that accept Medicaid exist, but reimbursement models for telemedicine vary sharply across jurisdictions, and a platform that bills Medicaid in one state may not be licensed or reimbursed to do so in another. Before booking, ask any telehealth provider directly whether it accepts your specific state Medicaid plan — not just whether it “accepts Medicaid” in general, which can mean almost nothing.
The orthopedic data covers one specialty in one study. Refusal rates in psychiatry, dermatology, and pain management are not captured in the same dataset, and patients in those areas should treat their own access experience as data worth documenting and reporting to their state Medicaid office.
This section presents general health system information for educational purposes and does not constitute medical or legal advice. Consult a qualified healthcare professional for guidance specific to your situation.
Why does telemedicine reimbursement vary so much between states and countries?
Telemedicine reimbursement varies so much between states and countries because no single payer sets the rules — Medicaid, private insurers, national health systems, and out-of-pocket markets each write their own coverage policies, and those policies rarely align. For patients, that gap translates directly into whether a video visit costs nothing, costs full price, or simply isn’t covered at all.
Start with Medicaid in the United States. A scoping review of public reimbursement models across national and subnational jurisdictions found that coverage decisions differ between countries and between states and provinces within the same country — meaning a Medicaid enrollee in one state may get a teledermatology visit fully reimbursed while an enrollee two states over gets nothing. That isn’t a glitch. It’s the predictable result of leaving reimbursement policy to dozens of separate administrative bodies with different budgets, political priorities, and lobbying pressures.
The same scoping review identified three broad reimbursement structures governments use: fee-for-service models, where providers bill per visit and reimbursement rates are set by the payer — rates that often run lower for telehealth than for equivalent in-person care; bundled or capitated payments, where a fixed amount covers a patient’s care regardless of how many telehealth visits occur; and hybrid models that mix both, sometimes with separate telehealth billing codes and sometimes without any codes at all. When no billing code exists for a telehealth service, providers frequently can’t bill for it, so they stop offering it.
Outside the United States, the picture is equally fragmented. A qualitative study of telemedicine implementation in Ghana found that coverage, pricing, and reimbursement were among the most cited barriers to scaling telehealth services, with no standardized national framework governing what insurers or government programs would pay — leaving patients and providers to negotiate informally or absorb costs directly, according to researchers studying the Akoma Pa intervention.
Private insurers add another layer of inconsistency. Even within a single state, two patients with different commercial plans can face completely different cost-sharing for the same telehealth appointment. Insurers set their own telehealth tiers, and those tiers change with contract cycles.
Before you book a telehealth appointment, ask your insurer in writing whether the specific service type — not just “telehealth” generically — is covered, what the billing code will be, and whether the provider is in-network for telehealth specifically. In-network status for in-person care does not automatically carry over.
This section presents general information about telemedicine reimbursement systems and is not medical advice. Consult a qualified healthcare professional for guidance specific to your situation.
What payment barriers block opioid use disorder treatment for Medicaid enrollees?
Payment barriers block Medicaid enrollees from opioid use disorder treatment at nearly every step of the care process, and Medicaid specialist access to medications like buprenorphine remains inconsistently covered across states. A critical review published in 2024 found that prior authorization requirements, quantity limits, and pharmacy-level restrictions combine to delay or deny treatment for patients who already face significant logistical hurdles.
Prior authorization delays. Many Medicaid programs require prescribers to obtain approval before dispensing buprenorphine or methadone. The 2024 critical review documents that these approval processes can take days to weeks—a window during which patients in early recovery face high risk of relapse or overdose.
Quantity and dose limits. Some state Medicaid programs cap the number of doses or the total daily dose a patient can receive, regardless of what a prescriber determines is clinically appropriate. The same review identifies dose caps as a direct mechanism through which payment policy overrides clinical judgment.
Pharmacy restrictions. Even when a prescription clears prior authorization, patients may find that their local pharmacy does not stock the medication or does not accept their Medicaid plan for that specific drug. Rural and low-income urban patients face this most acutely.
Prescriber reimbursement gaps. Low Medicaid reimbursement rates push many physicians and nurse practitioners out of the program entirely. A national mystery caller study found that Medicaid patients calling specialist offices were turned away at significantly higher rates than privately insured callers, a pattern that extends to addiction medicine.
Telehealth coverage inconsistency. A scoping review of public reimbursement models found that telehealth coverage rules vary sharply across jurisdictions, with some Medicaid programs reimbursing audio-only visits at lower rates or not at all. For patients without broadband or a smartphone camera, audio-only is often the only option.
The 2024 critical review makes a specific point worth quoting directly: payment-related barriers are not incidental friction but structural features of how Medicaid programs have historically managed opioid use disorder treatment costs. Patients navigating telehealth platforms should ask any prospective provider, before the first appointment, exactly which Medicaid plan the platform accepts, whether prior authorization is required for their specific medication, and who handles that paperwork if it is.
This section presents general information drawn from published research and public records. It is not medical advice, and no content here should substitute for guidance from a licensed healthcare provider.
Does collaborative care for dementia actually lower Medicare costs?
Disclaimer: This content is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional for guidance specific to your situation.
Collaborative care for dementia lowers Medicare costs in some trial settings, but the savings are modest, unevenly distributed, and far from guaranteed once a program leaves a controlled research environment. A 2023 secondary analysis of the Care Ecosystem randomized clinical trial—a program that paired dementia patients with trained navigators who coordinated care across providers—found that Medicare spending dropped by roughly $2,585 per person per year among participants compared to a control group. That sounds meaningful. It is, with caveats.
The trial enrolled patients who already had Medicaid specialist access and Medicare coverage, a population that tends to have more documented care needs and more room for coordination to reduce redundant services. Savings came primarily from fewer emergency department visits and lower inpatient costs, not from reduced medication spending or outpatient care. The Care Ecosystem model assigned non-clinical navigators to handle logistics, answer caregiver questions, and flag problems before they escalated into hospitalizations. That mechanism matters because it tells you what you’re actually buying: a buffer against crisis care, not a cure for the underlying disease.
The trial data showed three key findings:
- The intervention group averaged $2,585 less in annual Medicare spending than controls.
- Savings concentrated in patients with more advanced dementia; people with milder disease showed little to no cost difference.
- The trial ran across three academic medical centers, which have coordination infrastructure that most community telehealth vendors lack.
That last point is where consumer skepticism earns its keep. Telehealth companies marketing “collaborative dementia care” programs often cite trials like Care Ecosystem to justify premium pricing or to attract Medicare Advantage contracts. The trial itself ran under research conditions with trained staff, institutional oversight, and a defined patient population. Replicating those results in a for-profit telehealth setting—where navigator training, caseload sizes, and follow-through protocols vary widely—remains an open question the published analysis does not answer.
Patients and caregivers evaluating these programs should ask vendors directly: what is your navigator-to-patient ratio, what training do navigators receive, and can you show outcome data from your own patient population rather than a cited academic trial? A company that cannot answer those questions with specifics is selling you a concept, not a demonstrated service.
What do physical rehabilitation patients say about telehealth coverage gaps?
Physical rehabilitation patients navigating Medicaid specialist access report a consistent pattern: coverage gaps are not rare edge cases but a structural feature of how telehealth reimbursement works in practice. A peer-reviewed study published in 2025 found that physical medicine and rehabilitation patients frequently cited insurance coverage uncertainty, out-of-pocket costs, and difficulty confirming whether a telehealth visit would be reimbursed at the same rate as an in-person one — problems that shaped whether patients even attempted to schedule care in the first place, according to PMID 40111042.
That same study surveyed both patients and providers in PM&R settings and found that patients valued telehealth for convenience and reduced travel burden, yet expressed frustration when coverage terms shifted without notice. Patients described situations where a visit they believed was covered resulted in unexpected bills. The coverage confusion itself became a barrier to care.
The access problem compounds for Medicaid enrollees specifically. A national mystery-caller study found that Medicaid patients attempting to reach specialized surgeons — a category that overlaps with post-surgical rehabilitation referrals — encountered appointment denial rates and coverage confusion that differed sharply from privately insured callers, with some practices refusing Medicaid patients outright, per PMID 39637372. Telehealth does not automatically fix that gatekeeping; a virtual visit with a specialist who doesn’t accept Medicaid remains inaccessible.
Reimbursement policy shifts constantly. A 2024 scoping review of public reimbursement models across national and subnational jurisdictions found that telehealth payment rules vary widely by geography, payer type, and service category — meaning a rehabilitation patient in one state may have full coverage for a telehealth PT evaluation while a patient two states over pays entirely out of pocket for the same session, as documented by PMID 40794105.
Patients report three recurring friction points: surprise billing after visits they believed were covered under their plan’s telehealth benefit; difficulty reaching anyone at their insurer who could confirm coverage before the appointment; and providers who offer telehealth but are not credentialed with the patient’s specific Medicaid managed care plan, creating a coverage gap even when both parties are technically “in-network” with the broader program.
The PMID 40111042 study found that providers shared some of these frustrations, reporting that reimbursement uncertainty affected their own willingness to expand telehealth offerings — a dynamic that shrinks the pool of available telehealth rehabilitation providers before patients even start searching.
This section presents general health system information for consumer awareness purposes and does not constitute medical advice, diagnosis, or treatment recommendations. Consult a qualified healthcare professional for guidance specific to your situation.
How are medical industry investments shaping senior health care access?
Medical industry investments are reshaping Medicaid specialist access for seniors in ways that cut both directions — expanding some services while concentrating care in markets that generate the highest returns. Private capital flows toward profitable service lines and away from the low-reimbursement coverage gaps where older, lower-income patients are most likely to need help.
A 2024 research analysis on strategic investment patterns in senior health found that industry spending clusters around conditions with predictable, high-volume billing opportunities. Dementia care is one example. A randomized clinical trial secondary analysis found that a coordinated care model for Medicare beneficiaries with dementia reduced total health care costs — yet that kind of care coordination model attracts less private investment than device sales or specialty procedures, because the savings accrue to payers, not to the companies doing the investing.
The access gap is measurable. A national mystery-caller study on Medicaid coverage and specialist access found that patients on Medicaid faced significantly higher rates of appointment refusal and longer wait times than privately insured patients when trying to reach specialized surgeons. Seniors on Medicaid — a large and growing population — run into this wall constantly.
Telehealth was supposed to widen the door. It has, selectively. A scoping review of public reimbursement models across national and subnational jurisdictions found that reimbursement structures for telemedicine vary so widely that patients in lower-income brackets often cannot predict what they will owe until after a visit. That unpredictability reflects policy environments shaped partly by industry lobbying over what gets covered and at what rate.
What seniors navigating telehealth should watch for:
- Platforms backed by private equity often prioritize visit volume over continuity of care; ask whether the provider you see today will be available for follow-up.
- “Covered by Medicare/Medicaid” claims on telehealth marketing materials may not account for service-specific exclusions or state-level variation in reimbursement rules, a problem the scoping review documents across jurisdictions.
- Payment-related barriers documented in opioid use disorder treatment research show a consistent pattern: coverage gaps hit hardest in the populations with the fewest alternatives, and seniors with complex conditions face the same dynamic.
Investment shapes what gets built. Patients should ask who funded the platform they are using and what financial incentives govern the care they receive.
This section presents general health system information for educational purposes and is not medical advice. Consult a qualified healthcare professional for guidance specific to your situation.
FAQ
What does the research say about Medicaid specialist access to orthopaedic surgeons?
A national mystery-caller study published in the Journal of the American Academy of Orthopaedic Surgeons (PMID 39637372) found that Medicaid patients faced higher rates of appointment denial and longer quoted wait times than commercially insured callers. Medicaid specialist access to surgical subspecialties remains one of the most documented but least-fixed gaps in U.S. insurance coverage.
Are telemedicine reimbursement rules consistent across U.S. states?
No. A scoping review in the Journal of Medical Internet Research (PMID 40794105) found no uniform public reimbursement model across national or subnational jurisdictions. Coverage rules, eligible service types, and payment rates differ enough between states that providers cannot rely on a single compliance framework.
What payment problems block access to medications for opioid use disorder?
A critical review in the Journal of Substance Use and Addiction Treatment (PMID 38906417) identified prior authorization delays, restrictive pharmacy benefit designs, and reimbursement rates below the cost of dispensing as the main financial barriers. These obstacles disproportionately affect Medicaid enrollees, who have fewer alternative payer options.
Can collaborative telehealth models reduce costs for Medicare dementia patients?
A secondary analysis of a randomized clinical trial in JAMA Internal Medicine (PMID 37721734) found that the Care Ecosystem model reduced total Medicare spending for patients with dementia compared to usual care. The model relies on nurse navigators and remote coordination, but it has not been widely adopted or consistently funded.
What do physical medicine and rehabilitation patients think about telehealth coverage?
A study in the American Journal of Physical Medicine & Rehabilitation (PMID 40111042) found that both patients and providers saw telehealth as convenient but raised concerns about insurance coverage reliability and whether payers would continue reimbursing virtual visits after pandemic-era flexibilities expired. Uncertainty about coverage was a recurring theme.
Why did Ghana’s Akoma Pa telemedicine program struggle with pricing and reimbursement?
Qualitative research published in BMC Health Services Research (PMID 42415045) found that implementers could not agree on service pricing and had no formal reimbursement agreements with insurers, which stalled the program’s expansion. Without defined payment structures, even technically functional mHealth platforms fail to reach patients at scale.
How is the medical industry investing in senior health, and does it address access gaps?
A study in Frontiers in Public Health (PMID 40717942) analyzed strategic investment patterns in senior health and found that industry spending concentrates on technology products rather than on closing coverage or payment gaps for low-income older adults. Investment volume is growing, but it does not map onto the populations with the greatest unmet need.
Is this article medical advice?
No. This report presents general health information drawn from peer-reviewed research and is not a substitute for individualized medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before making any decisions about your care or coverage.
This article is for general information and is not medical, legal, or financial advice. Telehealth services, prescriptions, and insurance coverage vary by state and provider — verify a provider’s licensing and consult a qualified professional before making care decisions.